X T L Biopharmaceuticals LtdNASDAQ:XTLB
- LAST PRICE1.7953
- TODAY'S CHANGE (%)-0.0847 (-4.5053%)
- Bid / Lots1.6400/ 1
- Ask / Lots1.7600/ 1
- Open / Previous Close1.7700 / 1.8800
- Day Range
- 52 Week Range
- Volume1,969
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XTLB |
|---|---|---|
| 09:32 ET | 602 | 1.77 |
| 09:44 ET | 100 | 1.79 |
| 09:53 ET | 1150 | 1.7953 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
X T L Biopharmaceuticals Ltd | 23.7M | -5.5x | --- |
Tempest Therapeutics Inc | 23.7M | -0.6x | --- |
Neurosense Therapeutics Ltd | 23.9M | -2.8x | --- |
Lisata Therapeutics Inc | 24.2M | -1.1x | --- |
Onconetix Inc | 24.1M | 0.0x | --- |
Athira Pharma Inc | 24.6M | -0.2x | --- |
Company Information
XTL Biopharmaceuticals Ltd is an Israel-based biopharmaceutical company engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
Contact Information
- Headquarters
- 5 Badner St., P.O.Box 8241RAMAT GAN, NY, Israel 5218102
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Doron Turgeman
- Chief Executive Officer, Director
- Shlomo Shalev
- Chief Financial Officer
- Itay Weinstein
- Non-Executive Director
- Dobroslav Melamed
- Non-Executive Director
- Alexander Rabinovitch
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $23.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 12.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.24 |
EPS | $-0.33 |
Book Value | $0.41 |
P/E Ratio | -5.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
